Clinical trial · Observational
Cardio-Oncology Registry
Cardio-Oncologie: étude Pilote évaluant la faisabilité, Utilité Concrète, Interdisciplinaire d'Une Unité Spécialisée
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cardio-oncology is an emerging field. Most of the data available have been issued from either retrospective analysis, industry data or pharmacovigilance data. These data sources include a number of bias. CONFUCIUS is a single tertiary centre prospective registry including all patients who have been referred for cardio-oncology assessemnt. The objectives are to provide a comprehensive vue of cardoi-oncology, enable to detect early signals of cardiotoxicity and enhance ancillary projetcts aiming at specific populations (e.g., type of cancer) and/or drugs.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Arrhythmia | — | UNRESOLVED | — |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Cardiac Disease | — | UNRESOLVED | — |
| Heart Diseases | — | UNRESOLVED | — |
| Metabolic Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No interventions are planned | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Incidence of cardio-toxicty
- timeFrame
- 5 years
- description
- Number of patients with cardiotoxicity in a cohort of patients referred to a cardio-oncology clinic
Secondary outcomes (10)
- measure
- Analysis of cardiotoxicity
- timeFrame
- 5 years
- description
- Correlation of cardio-toxicity overall, and in predefined subgroups; statistical associatoin with outcomes.
- measure
- Analysis of cardioprotective strategies
- timeFrame
- 5 years
- description
- Correlation between the use of cardiovascular drugs and the number of patients with cardiotoxicity.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * referred to cardio-oncology Exclusion Criteria: * refusal to participate
References
Publications (0)
Data not yet available